Soleo Health Chief Executive Officer Drew Walk Named to NHIA Board of Directors

Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today the appointment of Chief Executive Officer Drew Walk to the National Home Infusion Association (NHIA) 2023-2024 Board of Directors.

Drew Walk joins a group of seasoned home infusion experts on the NHIA board, an industry governing body. NHIA is the leading industry association providing education, information, advocacy and resources for the nation’s home and alternate site infusion provider community and the manufacturers, suppliers and service companies who support them. As a leading voice for the home infusion industry on Capitol Hill and with the Administration, NHIA advocates for the industry, ensuring that federal policy supports equitable access to the full range of home infusion therapies and related services.

“It is both a privilege and an honor to be asked to serve on NHIA’s Board of Directors alongside industry leaders and individuals who lead well-established and respected companies in the home infusion arena. I am proud to have an opportunity to add my voice to theirs as we work collectively to further the important role home infusion plays for all stakeholders – patients, payors, physicians, health systems and pharmaceutical manufacturers,” Walk said of his Board appointment.

“In my Board position, I hope to advance the key issues we face as an industry and find solutions that assist in enhancing patient care. These include, among others, addressing the changing regulatory landscape and reimbursement environment as well as facilitating technology across all communication channels including patient-provider and patient-pharmacy since the use of telehealth initiatives are on the rise,“ Walk concluded.

Connie Sullivan, BSPharm, NHIA president and chief executive officer, commented on Walk’s Board appointment: “We welcome Drew to the NHIA Board, which we expanded this term to 15 total seats to allow for broader diversification of infusion provider organization representation. Over the course of his career, Drew has worked with various types of healthcare entities which allows him to bring a broad range of experience to all stakeholders. We look forward to Drew’s contributions to our constituents and Board.”

The 2023-2024 Board of Directors will be installed after NHIA’s Annual Conference in Washington, D.C., March 25-29, 2023. Each will serve a three-year term.

Drew Walk has been involved in the home infusion industry since 1985. Trained as a pharmacist, he has held roles of increasing responsibility at health systems, small independent infusion pharmacies and large national providers. This directly speaks to the range and depth of his experience. Walk’s new appointment marks the second time he has served on the NHIA Board, the first being a four-year term from 2010-2014.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.